Acorda is down 6%, Auxilium is down 35%, Dendreon is down 27%, and Momenta is down 30%.
FORBES: Biotech, Where Winners Lose
This piece was written by Ron Cohen, the chief executive of Acorda Therapeutics.
FORBES: How The U.S. Can Attract Biotech Firms By Imitating China
Ampyra, a pill approved to help patients with multiple sclerosis walk, has put Acorda Therapeutics in the small club of profitable biotechnology companies.
FORBES: Drug That Helps Multiple Sclerosis Patients Walk May Also Aid Stroke Victims
应用推荐
模块上移
模块下移
不移动